1. IndiaInfoline
  2. Search
Displaying Results for "lupin"
Showing Results 1 - 19 of 1601

Lupin explores opportunities for organic and inorganic growth

India Infoline News Service  | Mumbai December 18, 2014 12:44 IST

Earlier Exchange has sought clarification from Lupin Ltd with respect to news article appearing in Economic Times on December 15, 2014 titled "Scouting for Acquisitions"

Lupin allots equity shares

capital market  | Mumbai December 17, 2014 17:24 IST

Of Rs 2 each

Lupin plans acquisition

India Infoline News Service  | Mumbai December 15, 2014 09:56 IST

Report stated that the company is looking at ramping up its India business, with new product launches.

Lupin gains on launch of generic for Celebrex

India Infoline News Service  | Mumbai December 12, 2014 12:36 IST

The stock is now trading with a gain of 1.4 per cent.

Lupin gains after US subsidiary launches generic for Celebrex

capital market  | Mumbai December 11, 2014 12:42 IST

Lupin gained 0.77% to Rs 1,441.95 at 13:00 IST on BSE after the company announced that its US subsidiary launched the authorized generic for G.D. Searle LLC's Celebrex Capsules.

Lupin launches Authorized Generic for Celebrex Capsules

India Infoline News Service  | Mumbai December 11, 2014 12:28 IST

At 12.30 PM, the stock was up 0.43% at Rs. 6.20.

Lupin scales record high on hopes of hike in foreign investment limit

capital market  | Mumbai November 24, 2014 12:01 IST

Lupin rose 1.22% to Rs 1,482 at 12:01 IST on BSE on reports a government panel has cleared the company's request to raise foreign investment limit in the firm.

Lupin allots equity shares

capital market  | Mumbai November 19, 2014 11:04 IST

Under stock option plan

Lupin receives FDA approval for Generic Celebrex Capsules

India Infoline News Service  | Mumbai November 03, 2014 13:18 IST

Lupin is the 5th largest and fastest growing top 5 generics player in the US.

Lupin receives final approval for Celecoxib Capsules

capital market  | Mumbai November 03, 2014 12:37 IST

From USFDA

Lupin (Q2 FY15)

India Infoline Research Team  | Mumbai October 30, 2014 17:21 IST

Lupin reported a subdued quarter on sequential basis on the back of a stellar Q1 as revenues declined 5% qoq (+~19% yoy) vs our estimate of +0.2% qoq and 25.4% yoy.

Lupin's results margins reflect base business strength: IIFL Institutional Report

India Infoline News Service  | Mumbai October 30, 2014 09:11 IST

Strong growth prospects in other territories and an improved margin profile make Lupin one of our best picks in large-cap pharma space

Lupin

capital market  | Mumbai October 29, 2014 13:15 IST

US business declined on QoQ basis

Lupin standalone net profit declines 43.20% in the September 2014 quarter

capital market  | Mumbai October 28, 2014 16:52 IST

Sales rise 3.77% to Rs 2207.48 crore

Lupin closes down; Q2 net profit at Rs6.3bn

India Infoline News Service  | Mumbai October 28, 2014 16:18 IST

Lupin closed down 2.45% at Rs.1,359 on NSE as against the previous close of Rs. 1,358

Lupin declines after declaring Q2 result

capital market  | Mumbai October 28, 2014 14:29 IST

Lupin slipped 1.65% to Rs 1,371.10 at 14:25 IST on BSE, in volatile trade after announcing Q2 result during market hours today, 28 October 2014.

Lupin extends fall after declaring Q2 result

capital market  | Mumbai October 28, 2014 13:53 IST

Lupin fell 1.29% to Rs 1,376 at 13:45 IST on BSE, with the stock extending intraday fall in volatile trade after announcing Q2 result during market hours today, 28 October 2014.

Lupin Q2 net profit at Rs. 6.3bn

India Infoline News Service  | Mumbai October 28, 2014 13:47 IST

The net profit of the pharma company increased to Rs 630 crore as against Rs. 406 crore in the same quarter last fiscal.

Lupin net at Rs630 crore; stock slips

India Infoline News Service  | Mumbai October 28, 2014 13:38 IST

At 1:37PM, Lupin was trading down 1% at Rs. 1379 as against the previous close of Rs. 1394

Back to Top

 

 
 
Reports
News